Tag: medical cannabis

FSD Pharma reports positive pre-clinical results for proprietary CBD combination product

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) reports today that its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann”), has achieved positive results in a pre-clinical efficacy study of its proprietary “Steady Stomach” CBD combination product for Inflammatory Bowel Disease (IBD). Under the terms of the agreement between FSD and SciCann, FSD Pharma holds exclusive marketing and distribution rights for the “Steady Stomach” product in Canada. read more

FSD Pharma Completes Harvest and Microbial Testing of First Lot

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) is pleased to announce that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), a licensed cannabis producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”), completed the harvest of its first lot of cannabis and successfully passed microbial testing required by Health Canada under the ACMPR and will be harvesting its second lot this week so as to conduct full analytical testing, thereby positioning FV Pharma to request a Pre-Sales License Inspection from Health Canada. The Pre-Sales License Inspection is the last step prior to the issuance of a Sales License under the ACMPR. read more

FSD Pharma Announces Listing on Frankfurt Stock Exchange

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTC: FSDDF) announced today that its subordinate voting shares are now listed on the Frankfurt Stock Exchange (“FRA”) and are trading under the “WKN: A2JM6M” and the ticker symbol “0K9.” The Company’s subordinate voting shares continue to be listed on the Canadian Stock Exchange (“CSE”) under the ticker symbol “HUGE” and on the OTC in the US under the ticker symbol “FSDDF.” read more

FSD Pharma Quebec Partner Cannara Biotech Closes Over $17.6 Million Equity Financing to Begin Build Out of First Phase of 625,000 Square Foot Indoor Grow

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC:FSDDF) is pleased to announce its strategic partner Cannara Biotech Inc. (“Cannara”) closed $17.66 million common share equity financing. read more

FSD Pharma Appoints a Special Committee of the Board for Mergers and Acquisitions and Interim Chief Financial Officer

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

Thomas Fairfull, President and Chief Executive Officer of FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC:FSDDF), is pleased to announce the appointment of a Special Committee of the Board of Directors to focus on Merger and Acquisition Opportunities and also the appointment of Donal Carroll as interim Chief Financial Officer. read more

FSD Pharma Surpasses One Billion Shares Traded and Makes History With Annual CSE Volume Trading Record in Less Than Two Months

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF), is pleased to report that it has traded over one Billion Class B subordinate voting shares and has broken the one year consecutive days of trading record on the Canadian Securities Exchange (“CSE”) in less than two months of trading. During the period of May 29, 2018 to July 18, 2018, the Company traded exactly 1,028,297,481 Class B subordinate voting shares on the Canadian Securities Exchange (“CSE”). Comparatively, the largest amount traded prior on the CSE in a one year period of consecutive days was 989,295,522. This is the largest total quantity of share volume ever traded by a CSE listed issuer within one year of consecutive days of trading as confirmed by the CSE. read more

FSD Pharma Enters Into Saskatchewan Wholesale Supply MOU of up to 5,000 Kilograms With High Tide Ventures

MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD Pharma”) (CSE:HUGE) (OTC:FSDDF) today announced that its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) has entered into a non-binding memorandum of understanding (“MOU”) with High Tide Ventures Inc. (“High Tide”) dated July 18, 2018 to supply the Saskatchewan market on a wholesale basis with up to 5,000 kilograms of cannabis products over the next year when available. FSD Pharma is working together with Auxly (formerly Cannabis Wheaton Income Corp.) (TSX.V:XLY) to achieve its mission to develop the largest hydroponic indoor cannabis cultivation facility in Cobourg, Ontario, Canada. read more

FSD Pharma Inc. announces acquisition to expand in Newfoundland for production and sales

•Strategic investment of $40 million to bring economic benefits to province of Newfoundland
MotherlodeTV
C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD” or the “Company”) (CSE:HUGE) (OTC: FSDDF) is pleased to announce a binding agreement to purchase 51% of Atlantic Island Cannabis Inc. (to be renamed FSD Atlantic Pharma Inc.) effective July 4, 2018. The agreement involves a strategic investment of $40 million to drive production and sales of legal cannabis in the province of Newfoundland. In the first phase of the project, an indoor high quality 45,000 square foot cannabis production facility will be set up in Freshwater, Carbonear, Newfoundland. This site is expected to bring about economic benefits for the province and to create 200 local, management and construction jobs through a phased expansion approach. Phase two of the project will involve a further expansion of the indoor grow facility to up to approximately 300,000 square feet for the production and processing of legal cannabis. read more